NOV 17, 202665 MINS READ
Creatine phosphate arginine salt (also termed phosphocreatine arginine or creatine phosphate diarginine) is a novel pharmaceutical compound designed to address limitations inherent in conventional sodium salts of phosphocreatine 1. The chemical structure is defined as N-{imino(phosphonoamino)methyl}-N-methylglycine diarginine salt, with the molecular formula corresponding to one creatine phosphate anion complexed with two L-arginine cations 1. This stoichiometric arrangement yields a compound that exists optionally as a hydrate, with crystallographic studies indicating stable hydrogen bonding networks between the guanidinium groups of arginine and the phosphate moiety of creatine phosphate 1.
The formation of this salt addresses two critical pharmaceutical challenges: first, it eliminates the vascular irritation and hypernatremia risk associated with high-dose sodium phosphocreatine administration; second, it creates a synergistic pharmacological entity where both components contribute independently to myocardial protection 1. Spectroscopic characterization via Fast Atom Bombardment Mass Spectrometry (FAB-MS) reveals a characteristic mass-to-charge ratio, while 31P-NMR spectroscopy confirms the integrity of the N-phosphoryl bond under physiological pH conditions 1. The compound demonstrates enhanced aqueous solubility compared to free creatine phosphate (solubility >200 mg/mL at 25°C), facilitating intravenous formulation for clinical cardioplegia applications 1.
Thermal gravimetric analysis (TGA) indicates that the dihydrate form loses coordinated water molecules at 80–95°C, with decomposition of the organic framework occurring above 180°C 1. Differential scanning calorimetry (DSC) shows an endothermic transition corresponding to the melting point of the anhydrous form at approximately 165–170°C 1. These thermal properties are critical for formulation stability during sterilization processes and long-term storage under ambient conditions.
The creatine kinase (CK) system constitutes a temporal and spatial energy buffering mechanism operative in tissues with high and fluctuating ATP demand, including skeletal muscle, cardiac myocytes, neurons, and retinal photoreceptors 2,7,9. The reversible reaction catalyzed by creatine kinase is:
Phosphocreatine + ADP + H⁺ ↔ ATP + Creatine
This reaction proceeds with a standard free energy change (ΔG°') of approximately −12.5 kJ/mol in the direction of ATP synthesis, ensuring efficient energy transfer when cellular ATP/ADP ratios decline during intense metabolic activity 2,7. Creatine kinase exists as multiple isoenzymes with distinct subcellular localizations: mitochondrial CK (mtCK) couples oxidative phosphorylation to phosphocreatine synthesis, while cytosolic isoforms (MM-CK in muscle, BB-CK in brain) facilitate ATP delivery to myofibrils and ion pumps 9,10,14.
During high-intensity exercise lasting approximately 10 seconds, phosphocreatine serves as the primary fuel for ATP regeneration, with skeletal muscle phosphocreatine concentrations declining from ~25 mM to <5 mM 2,7. Supplemental creatine administration (typically 5–20 g/day) increases intramuscular phosphocreatine stores by 10–40%, thereby enhancing peak power output and delaying fatigue onset during repeated sprint activities 2,3,6. The rate-limiting step in this system is often the availability of free creatine and the activity of creatine kinase, both of which can be modulated by metabolic interventions 9,10,13.
L-arginine serves as the immediate precursor for creatine biosynthesis through a two-organ, three-enzyme pathway 2,5,7,8. The initial step occurs in the kidney, where L-arginine:glycine amidinotransferase (AGAT) catalyzes the transfer of the guanidino group from arginine to glycine, yielding guanidinoacetate and regenerating L-ornithine 8. The reaction stoichiometry is:
L-Arginine + Glycine → Guanidinoacetate + L-Ornithine
Guanidinoacetate is then transported via the bloodstream to the liver, where guanidinoacetate N-methyltransferase (GAMT) catalyzes S-adenosylmethionine-dependent methylation to produce creatine 2,5,7,8. Finally, creatine is phosphorylated by creatine kinase in target tissues to form phosphocreatine, with this terminal step requiring Mg²⁺-ATP as the phosphoryl donor 8. The entire pathway consumes one molecule of arginine, one glycine, and one S-adenosylmethionine per creatine molecule synthesized, representing a significant metabolic investment 5,8.
Arginine availability can become rate-limiting for creatine synthesis under conditions of rapid growth, intense exercise, or dietary arginine restriction 5,6. Supplementation studies demonstrate that combined arginine and creatine administration produces greater increases in muscle phosphocreatine content than creatine alone, suggesting that endogenous arginine pools may be insufficient to maximize creatine biosynthesis during high-demand states 3,6. This metabolic interdependence forms the biochemical rationale for co-formulating arginine with creatine phosphate in therapeutic applications 1,3,6.
Beyond its role in creatine biosynthesis, L-arginine serves as the sole substrate for nitric oxide synthase (NOS) enzymes, which catalyze the five-electron oxidation of arginine to produce nitric oxide (NO) and L-citrulline 3,5,6. Three NOS isoforms exist: neuronal NOS (nNOS/NOS1), inducible NOS (iNOS/NOS2), and endothelial NOS (eNOS/NOS3), each with distinct regulatory mechanisms and tissue distributions 5,6. The reaction proceeds as:
L-Arginine + 2O₂ + 1.5NADPH → NO + L-Citrulline + 1.5NADP⁺
Nitric oxide functions as a potent vasodilator by activating soluble guanylate cyclase in vascular smooth muscle, increasing cyclic GMP levels and promoting calcium sequestration 1,3,6. This mechanism is particularly relevant during exercise, where NO-mediated vasodilation enhances blood flow to active muscles, improving oxygen and nutrient delivery while facilitating metabolic waste removal 3,6. Chronic endurance training upregulates both NOS1 and NOS3 expression in skeletal muscle, indicating adaptive enhancement of the arginine-NO pathway in response to repeated contractile activity 6.
The arginine-NO system also exerts anti-thrombotic effects by inhibiting platelet aggregation and adhesion to endothelium, a property that contributes to the cardioprotective actions observed with arginine supplementation 1,6. In the context of creatine phosphate arginine salt, the arginine component provides substrate for NO synthesis, potentially augmenting coronary vasodilation and myocardial perfusion during ischemic episodes 1. This represents a key mechanistic distinction from sodium phosphocreatine, which lacks intrinsic vasodilatory capacity 1.
Myocardial ischemia rapidly depletes ATP stores, with concentrations falling from ~5 mM to <1 mM within 10–15 minutes of coronary occlusion 1,4,13. This energetic crisis impairs ion pump function, leading to intracellular sodium and calcium accumulation, cellular edema, and ultimately irreversible injury if reperfusion is delayed 4,13. Exogenous phosphocreatine administration provides an immediate, kinase-independent source of high-energy phosphate that can partially restore ATP levels even under anaerobic conditions 1,4,13.
Pharmacological studies demonstrate that phosphocreatine infusion (50–100 mg/kg IV) prior to or during ischemia reduces infarct size by 30–50% in animal models of coronary artery ligation 1,4,13. The protective mechanism involves: (1) direct phosphorylation of ADP by residual creatine kinase activity; (2) stabilization of mitochondrial membrane potential; (3) reduction of reactive oxygen species (ROS) generation during reperfusion; and (4) preservation of sarcolemmal Na⁺/K⁺-ATPase function 4,13. These effects are dose-dependent, with maximal protection observed at phosphocreatine concentrations of 5–10 mM in the extracellular space 1,13.
The addition of arginine to phosphocreatine formulations enhances cardioprotection through complementary mechanisms 1,3,6. Arginine-derived NO improves coronary collateral flow during ischemia, reducing the severity of the initial insult 1,6. Furthermore, NO inhibits mitochondrial respiration at complex IV (cytochrome c oxidase) in a reversible manner, effectively reducing oxygen consumption and extending the viability window during low-flow states 6. Post-reperfusion, NO scavenges superoxide anions (O₂⁻) to form peroxynitrite, which, despite its own oxidative potential, prevents the more damaging hydroxyl radical formation via Fenton chemistry 6.
Emerging evidence indicates that the creatine kinase system directly influences glucose homeostasis and insulin signaling 4,9,10,13,14. Creatine analogues such as cyclocreatine and β-guanidinopropionic acid reduce blood glucose levels in diabetic animal models by 20–40% within 2–4 hours of administration, independent of changes in insulin secretion 4,9,10,13. The mechanism involves enhanced glucose uptake in skeletal muscle via increased GLUT4 translocation to the plasma membrane, a process normally stimulated by insulin and muscle contraction 4,13.
Creatine kinase activity modulates the AMP-activated protein kinase (AMPK) pathway, a master regulator of cellular energy status 4,13,14. Depletion of phosphocreatine increases the AMP/ATP ratio, activating AMPK and promoting glucose transporter expression, glycolysis, and mitochondrial biogenesis 13,14. Conversely, phosphocreatine supplementation stabilizes ATP levels, reducing AMPK activation but improving insulin sensitivity through alternative mechanisms involving protein kinase B (Akt) phosphorylation 4,13.
Arginine supplementation independently improves glucose metabolism by stimulating insulin secretion from pancreatic β-cells 4,5. Arginine acts as a secretagogue at concentrations >2 mM, depolarizing β-cell membranes and triggering calcium influx through voltage-gated channels 4. However, this effect is transient and does not produce sustained hyperinsulinemia, distinguishing arginine from sulfonylurea drugs 4. In combination with phosphocreatine, arginine may optimize the metabolic environment for glucose utilization by simultaneously enhancing insulin availability and cellular ATP regeneration capacity 1,4.
Oxidative stress plays a central role in ischemia-reperfusion injury, with ROS generation peaking during the initial minutes of reperfusion as oxygen reintroduces electron flow through partially reduced mitochondrial complexes 6,13. Phosphocreatine exhibits direct antioxidant properties by stabilizing creatine kinase, an enzyme highly susceptible to oxidative inactivation via cysteine residue modification 3,6. Arginine-derived NO also functions as an antioxidant by scavenging superoxide radicals, although excessive NO production can paradoxically contribute to nitrosative stress through peroxynitrite formation 6.
The arginine metabolite agmatine, produced via arginine decarboxylase, demonstrates neuroprotective and cardioprotective effects independent of NO synthesis 5. Agmatine acts as an endogenous ligand for imidazoline receptors and α2-adrenergic receptors, producing antihypertensive effects and reducing sympathetic outflow 5. In experimental models, agmatine administration (10–40 mg/kg) reduces myocardial infarct size and improves post-ischemic contractile recovery, effects attributed to reduced catecholamine release and improved microvascular perfusion 5.
Inflammatory cytokine production (TNF-α, IL-1β, IL-6) is attenuated by both phosphocreatine and arginine through distinct mechanisms 1,5,6. Phosphocreatine reduces NF-κB activation by maintaining cellular ATP levels and preventing the energetic crisis that triggers inflammatory signaling 13. Arginine-derived NO inhibits leukocyte adhesion to endothelium and reduces neutrophil infiltration into ischemic tissues, limiting secondary inflammatory injury 6. These anti-inflammatory actions contribute to the long-term benefits of creatine phosphate arginine therapy in chronic heart failure and post-infarction remodeling 1.
The synthesis of creatine phosphate arginine salt involves initial preparation of free phosphocreatine acid followed by neutralization with L-arginine base 1. A representative procedure begins with 25.5 g of sodium phosphocreatine dissolved in 500 mL deionized water, which is then passed through a column packed with 732-type cation exchange resin (H⁺ form) to remove sodium ions 1. The eluate, containing free phosphocreatine acid (pKa ~4.5 for the phosphate group), is collected and immediately neutralized to prevent hydrolytic degradation of the N-phosphoryl bond 1.
L-arginine (17.4 g, 2 molar equivalents relative to phosphocreatine) is dissolved in a minimal volume of water and added dropwise to the phosphocreatine acid solution with continuous stirring at 4°C 1. The pH is monitored and maintained between 6.5–7.5 during addition to ensure complete salt formation without excess free base 1. The resulting solution is concentrated under reduced pressure at temperatures not exceeding 40°C to prevent thermal decomposition, yielding a viscous syrup that crystallizes upon addition of ethanol (3:1 ethanol:water ratio) 1.
Crystalline creatine phosphate arginine dihydrate is collected by filtration, washed with cold ethanol, and dried under vacuum at room temperature 1. Purity is assessed by high-performance liquid chromatography (HPLC) using a C18 reversed-phase column with UV detection at 210 nm, typically yielding >98% purity with <0.5% residual sodium 1. The dihydrate form is preferred for pharmaceutical applications due to superior stability during storage, with <2% degradation observed after 24 months at 25°C in sealed containers 1.
Alternative synthetic approaches involve direct reaction of creatine with phosphorylating agents (e.g., phosphorus oxychloride, polyphosphoric acid) in the presence of arginine, but these methods produce lower yields and require more extensive purification to remove inorganic phosphate impurities 11. Enzymatic synthesis using creatine kinase, ATP, and 3-phosphoglycerate as a phosphate donor has been described but is economically impractical for large-scale production 11.
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| GUANGDONG ZONK DRUG R & D LIMITED | Cardiac surgery cardioplegia solutions and treatment of myocardial ischemia-reperfusion injury in patients requiring myocardial metabolic support. | Creatine Phosphate Arginine Salt | Eliminates vascular irritation and hypernatremia risk associated with sodium phosphocreatine; synergistic myocardial protection through dual mechanisms of ATP regeneration and nitric oxide-mediated vasodilation. |
| ADVOCARE INTERNATIONAL L.P. | High-intensity athletic performance enhancement, bodybuilding, and endurance training requiring rapid ATP regeneration during brief bursts of activity lasting approximately 10 seconds. | Cellular Energy Enhancement Formula | Increases phosphocreatine levels in skeletal muscle by 10-40%, enhancing ATP turnover during maximal exercise; combines creatine with L-arginine-α-ketoglutarate for improved muscle perfusion and energy metabolism. |
| DANA-FARBER CANCER INSTITUTE INC. | Treatment of hyperglycemia, insulin-dependent diabetes mellitus, impaired glucose tolerance, and metabolic disorders in patients with dysregulated glucose metabolism. | Cyclocreatine Glucose Metabolism Modulator | Reduces blood glucose levels by 20-40% within 2-4 hours through enhanced GLUT4 translocation and improved insulin sensitivity; modulates creatine kinase system to regulate cellular energy status and glucose homeostasis. |
| ERIC H. KUHRTS | Extended athletic activity and bodybuilding requiring prolonged energy supply to muscles with enhanced vascular reactivity and reduced oxidative stress during intense training. | Sustained-Release Creatine-Arginine Complex | Prolongs muscle perfusion period through sustained vasodilation; preserves creatine kinase integrity via nitric oxide antioxidant capacity, enhancing creatine-to-phosphocreatine conversion efficiency. |
| ANN DE WEES ALLEN | Treatment of biological conditions associated with dysregulated arginine metabolism, including cardiovascular disorders, metabolic dysfunction, and conditions requiring enhanced creatine biosynthesis or nitric oxide production. | Arginine Metabolism Modulation System | Selectively directs arginine through specific metabolic pathways to produce creatine, nitric oxide, polyamines, or agmatine; corrects dysregulated arginine metabolism for targeted therapeutic outcomes. |